Survey with Ipsos to gain insights human-animal bond Survey with Ipsos to gain insights human-animal bond Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.
collaboration criving innovation collaboration criving innovation In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
A Unique Bond: human and animal health A Unique Bond: human and animal health At Boehringer Ingelheim we are dedicated to animal and human health. We celebrate the truly unique bonds between people and their pets.
License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments
PREVEXXION® RN: Marek’s disease vaccine available in EU UK PREVEXXION® RN: Marek’s disease vaccine available in EU UK Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
Boehringer and ZEISS partnership eye diseases Boehringer and ZEISS partnership eye diseases Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
FDA approves Jardiance treatment chronic kidney disease FDA approves Jardiance treatment chronic kidney disease U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease
Stargardt Disease Stargardt Disease Stargardt Disease is a hereditary condition which causes degeneration of cells in the retina at the back of the eye.
Interstitial lung disease in rheumatoid arthritis (RA-ILD) Interstitial lung disease in rheumatoid arthritis (RA-ILD) Interstitial lung disease (ILD) is the most common type of lung condition associated with the systemic autoimmune disease rheumatoid arthritis (RA).
Making more health through animal health Making more health through animal health Boehringer Ingelheim and Ashoka aim to build a world with a greater access to health for people, animals and their communities.
Full data chronic kidney disease trial efficacy Full data chronic kidney disease trial efficacy Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
LastMile initiative to address barriers in animal healthcare LastMile initiative to address barriers in animal healthcare The ‘LastMile’ initiative addresses major barriers in animal healthcare sector in Sub-Saharan African
FDA accepts new chronic kidney disease treatment application FDA accepts new chronic kidney disease treatment application FDA accepts new chronic kidney disease treatment application
Partnership for new liver disease treatments with Ribo Partnership for new liver disease treatments with Ribo Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Chronic kidney disease in cats Chronic kidney disease in cats Detect and manage chronic kidney disease and high blood pressure in cats
Rare Diseases: Rare but not alone Rare Diseases: Rare but not alone We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.
Animal Health partnering interests Animal Health partnering interests Animal Health partnering interests
Big hearts united to help animals in Ukraine Big hearts united to help animals in Ukraine Veterinaries volunteer at the Polish-Ukrainian border to help welcome Refugees and their animals. Refugees don’t rest until their animals are safe.
Central Nervous System Diseases Central Nervous System Diseases Find out more about our research and development in central nervous system diseases
Chronic kidney disease is a silent killer Chronic kidney disease is a silent killer Living with chronic kidney disease can have drastic impacts on a patient and their family’s life. A patient and her caregiver share their story on managing it.